The House Energy & Commerce Committee today unveiled a new package for the Prescription Drug User Fee Act (PDUFA). After the release, BIO’s Chief Science Officer, Cartier Esham, made the following remarks:
"For more than thirty years, the FDA user fee programs have shown tremendous results in delivering life-saving medicines to patients who urgently need them. These agreements between the industry and FDA include important provisions to improve the use of real-world evidence, modernize, streamline, and diversify clinical trials, and ensure that the Agency has the resources necessary to support the world-leading innovation our companies bring to patients every day.
"While we are still analyzing the bill, we are pleased to see bipartisan support from the Energy & Commerce Committee for these critical public health programs. We are further encouraged that the Committee recognizes the importance of a timely reauthorization and has worked together to develop a bill that will continue the shared goal of transforming and improving patients’ lives for years to come. We look forward to working with the Committee on in the coming weeks to achieve that goal."